Format

Send to

Choose Destination
Cardiol Young. 2010 Oct;20(5):505-8. doi: 10.1017/S1047951110000545. Epub 2010 May 17.

Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease.

Author information

1
Department of Neonatology, Charité University Medicine Berlin, Germany. anja.pohl@charite.de

Abstract

Patients with cyanotic congenital cardiac disease often develop major aortopulmonary collaterals. Vascular endothelial growth factor is a key promoter of angiogenesis. Its soluble receptor-1 acts as a potent antagonist. We studied 30 infants with cyanotic congenital cardiac disease and 27 infants with acyanotic congenital cardiac disease. Central venous plasma vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 levels were measured before, and 24 and 96 hours after surgery. There was no difference between plasma vascular endothelial growth factor levels in infants with cyanotic and those with acyanotic congenital cardiac disease. In cyanotic infants, the soluble vascular endothelial growth factor receptor-1 levels tended to be higher than in the acyanotic infants. In conclusion, there is no significant difference in the plasma levels of vascular endothelial growth factor and its soluble receptor-1 between infants with cyanotic and those with acyanotic congenital cardiac disease.

PMID:
20470449
DOI:
10.1017/S1047951110000545
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center